Tesamorelin Research Information

Growth Hormone-Releasing Factor (GHRF) Analog

For Metabolic & Visceral Fat Research

⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.

📑 Contents

🔬 What is Tesamorelin?

Tesamorelin is a synthetic 44-amino acid peptide analog of human Growth Hormone-Releasing Factor (GRF) that acts as a potent agonist at the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH). It is the first and only FDA-approved treatment indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy.

Tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. It restores the body's natural pulsatile GH release pattern, offering a more physiological approach compared to exogenous GH administration. Tesamorelin is available in pen and freeze-dried vial formulations for research purposes.

⚡ How Tesamorelin Works

Tesamorelin works through a targeted mechanism to stimulate natural growth hormone release:

Tesamorelin restores pulsatile GH secretion and thereby offers a more physiological means of reducing visceral adipose tissue. The effects are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.

📋 Research Applications

📊 Clinical Studies

Meta-Analysis of Randomized Controlled Trials (ScienceDirect 2026)

• Five RCTs showed Tesamorelin significantly reduced visceral adipose tissue (MD: −27.71 cm², 95% CI [−38.37, −17.06]; P < 0.001)
• Trunk fat reduction: MD: −1.18 kg, 95% CI [−1.40, −0.96]; P < 0.001
• Hepatic fat percentage reduction: MD: −4.28%, 95% CI [−6.31, −2.24]; P < 0.001
• Lean body mass increase: MD: 1.42 kg, 95% CI [1.13, 1.71]; P < 0.001
• Waist circumference reduction: MD: −1.61 cm, 95% CI [−2.28, −0.95]; P < 0.001
• No significant changes in CD4+ T-cell counts
• Adverse events included arthralgia, myalgia, paresthesia, and injection-site reactions

HIV-Associated Lipodystrophy in INSTI Users (AIDS 2024)

• First dedicated data on Tesamorelin efficacy and safety among people with HIV on integrase inhibitor (INSTI)-based regimens
• Visceral fat decline: median −25 cm² vs +14 cm² with placebo (P = 0.001)
• Hepatic fat reduction: −4.2% vs −0.5% with placebo (P = 0.01)
• Trunk-to-appendicular fat ratio reduction: −0.1 vs 0.0 with placebo (P = 0.03)
• Well tolerated with similar frequency of adverse events, including hyperglycemia, between groups

FDA-Approved Dosing (EGRIFTA SV)

• FDA-approved dose: 1.4 mg (0.35 mL of reconstituted solution) injected subcutaneously once daily
• Reconstitute one vial of 2 mg lyophilized powder with 0.5 mL of diluent
• Administer immediately following reconstitution; discard any unused solution
• Not indicated for weight loss management; weight neutral effect
• Long-term cardiovascular safety has not been established

Pharmacokinetics

• Absolute bioavailability is low (< 4%)
• Elimination half-life is rapid, estimated at 0.3-0.6 hours
• Inter-individual variability is high, especially for AUC
• Volume of distribution: 10.48 to 20.19 L/kg

💉 Interactive Dosing Guide

Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:

⚠️ Safety & Precautions

Tesamorelin has been studied in clinical trials with a manageable safety profile. The most common adverse events in meta-analyses included arthralgia, myalgia, paresthesia, and injection-site reactions like erythema.

• Injection site reactions: Erythema, pain, or tenderness at injection site
• Arthralgia: Joint pain, commonly reported
• Myalgia: Muscle pain
• Paresthesia: Tingling or numbness
• Hyperglycemia: Similar frequency between tesamorelin and placebo groups

Important Safety Considerations:

• FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy
• Not indicated for weight loss management – weight neutral effect
• Long-term cardiovascular safety has not been established
• Do not use if allergic to tesamorelin or any ingredients
• Do not use if pregnant or breastfeeding

📚 References

• Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764.
• DailyMed - EGRIFTA SV (tesamorelin) FDA Labeling. Updated December 2025.
• NCATS Inxight Drugs - Tesamorelin. Inxight Drugs.
• EMA Withdrawal Assessment Report - Egrifta.
• Badran AS, Helal A, Ayesh H, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. ScienceDirect. 2026.
• Pharos - Tesamorelin. Illuminating the Druggable Genome.

This information is for educational and research purposes only. Always consult with a qualified healthcare professional.

Last updated: July 2026